Company Encyclopedia
View More
name
Anebulo Pharmaceuticals
ANEB.US
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
4.496 T
ANEB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Anebulo Pharmaceuticals Reports Q1 2026 Financial Results

    Anebulo Pharmaceuticals reported Q1 2026 financial results, with operating expenses of $2.3 million and a net loss of $2.2 million. The company has $10.4 million in cash reserves. Anebulo commenced a Phase 1 trial for its drug selonabant, targeting cannabis-induced toxicity in children, supported by a grant from the National Institute on Drug Abuse. The company is exploring strategic alternatives, including a potential reverse stock split, to address unmet needs in cannabis toxicity treatments.

    Tip Ranks·
    US
    ANEB
    +2.84%
    Tip Ranks·
    US
    ANEB
    +2.84%

    Anebulo Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    ANEB
    +2.84%
    LB filings·
    US
    ANEB
    +2.84%

    Anebulo Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    ANEB
    +2.84%
    LB filings·
    US
    ANEB
    +2.84%

    Anebulo Pharmaceuticals Board Approves Reverse Stock Split

    Anebulo Pharmaceuticals Inc. announced its Board's approval of a proposed reverse stock split of common stock, pending stockholder approval at a future special meeting. The meeting date is yet to be determined, and the Board is reviewing strategic alternatives. This AI-generated news is for informational purposes and not financial advice. Original content was published via EDGAR by Anebulo Pharmaceuticals.

    Reuters·
    US
    ANEB
    +2.84%
    Reuters·
    US
    ANEB
    +2.84%

    Anebulo Pharmaceuticals Secures $994,300 NIH Grant for Pediatric Cannabis Toxicity Drug Trial

    Anebulo Pharmaceuticals Inc. has secured a $994,300 grant from the NIH to support its Phase 1 study of selonabant, aimed at treating acute cannabis-induced toxicity in children. The study, approved by the FDA, focuses on the drug's safety and pharmacokinetics. The company is collaborating with NIDA and the FDA to develop selonabant for pediatric use.

    Reuters·
    US
    ANEB
    +2.84%
    Reuters·
    US
    ANEB
    +2.84%